AR119705A1 - Formulaciones liposomales y sus métodos de uso y preparación - Google Patents
Formulaciones liposomales y sus métodos de uso y preparaciónInfo
- Publication number
- AR119705A1 AR119705A1 ARP200100841A ARP200100841A AR119705A1 AR 119705 A1 AR119705 A1 AR 119705A1 AR P200100841 A ARP200100841 A AR P200100841A AR P200100841 A ARP200100841 A AR P200100841A AR 119705 A1 AR119705 A1 AR 119705A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- methods
- liposome
- liposomal formulations
- polar headgroup
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición que comprende: un liposoma que comprende: i) 1,2-dioleoil-sn-glicero-3-fosfoetanolamina o una de sus sales; y ii) (a) uno o más fosfolípidos que tienen un grupo de cabeza polar, en donde el grupo de cabeza polar comprende glicerol, colina, fosfato y serina y una cola de ácido graso que comprende una cadena alifática C₁₀₋₂₈ o (b) un éster de colesterol ácido, o tanto (a) como (b); y iii) polietilenglicol (PEG) conjugado con al menos un fosfolípido; y al menos un carbohidrato fosforilado endógeno encapsulado en el liposoma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826874P | 2019-03-29 | 2019-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119705A1 true AR119705A1 (es) | 2022-01-05 |
Family
ID=72666933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100841A AR119705A1 (es) | 2019-03-29 | 2020-03-27 | Formulaciones liposomales y sus métodos de uso y preparación |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220184107A1 (es) |
| EP (1) | EP3946365A4 (es) |
| JP (1) | JP2022527638A (es) |
| KR (1) | KR20210143906A (es) |
| CN (1) | CN113873998A (es) |
| AR (1) | AR119705A1 (es) |
| AU (1) | AU2020252005A1 (es) |
| BR (1) | BR112021019593A2 (es) |
| CA (1) | CA3134828A1 (es) |
| CL (1) | CL2021002512A1 (es) |
| CO (1) | CO2021014274A2 (es) |
| EA (1) | EA202192663A1 (es) |
| IL (1) | IL286713A (es) |
| MX (1) | MX2021011876A (es) |
| PE (1) | PE20212366A1 (es) |
| SG (1) | SG11202110623PA (es) |
| TW (1) | TW202102231A (es) |
| WO (1) | WO2020205530A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023205628A1 (en) * | 2022-04-18 | 2023-10-26 | City Of Hope | Lipid nanoparticles, nucleic acids, and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010112301A (ko) * | 1999-03-02 | 2001-12-20 | 질레스피 카롤 | 리포좀내에 생활성 복합체의 포집 |
| US7060291B1 (en) * | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
| EP1385479A4 (en) * | 2001-03-26 | 2006-12-06 | Alza Corp | LIPOSOMIC COMPOSITION FOR IMPROVED INTRA-CELLULAR RELEASE OF A THERAPEUTIC AGENT |
| AU2003205049B2 (en) * | 2002-01-09 | 2009-05-28 | Transave, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| US20090191259A1 (en) * | 2002-01-09 | 2009-07-30 | Transave, Inc. | Efficient liposomal encapsulation |
| EP2429658B1 (fr) * | 2009-05-14 | 2016-04-20 | Sanofi Pasteur | Procédé pour adjuver le lipopolysaccharide (LPS) des bactéries à gram-négatif |
| LT3046537T (lt) * | 2013-09-16 | 2021-12-10 | Glycomine, Inc. | Farmacinis angliavandenių preparatas, skirtas terapiniam panaudojimui |
| US20170165374A1 (en) * | 2015-11-18 | 2017-06-15 | Insmed, Inc. | Compositions and methods for treating bacterial infections |
-
2020
- 2020-03-27 AU AU2020252005A patent/AU2020252005A1/en active Pending
- 2020-03-27 KR KR1020217035257A patent/KR20210143906A/ko unknown
- 2020-03-27 MX MX2021011876A patent/MX2021011876A/es unknown
- 2020-03-27 EA EA202192663A patent/EA202192663A1/ru unknown
- 2020-03-27 US US17/593,755 patent/US20220184107A1/en active Pending
- 2020-03-27 PE PE2021001645A patent/PE20212366A1/es unknown
- 2020-03-27 CN CN202080038191.4A patent/CN113873998A/zh active Pending
- 2020-03-27 EP EP20782039.0A patent/EP3946365A4/en active Pending
- 2020-03-27 WO PCT/US2020/025246 patent/WO2020205530A1/en active Application Filing
- 2020-03-27 TW TW109110461A patent/TW202102231A/zh unknown
- 2020-03-27 CA CA3134828A patent/CA3134828A1/en active Pending
- 2020-03-27 JP JP2021560323A patent/JP2022527638A/ja active Pending
- 2020-03-27 SG SG11202110623PA patent/SG11202110623PA/en unknown
- 2020-03-27 BR BR112021019593A patent/BR112021019593A2/pt unknown
- 2020-03-27 AR ARP200100841A patent/AR119705A1/es unknown
-
2021
- 2021-09-26 IL IL286713A patent/IL286713A/en unknown
- 2021-09-28 CL CL2021002512A patent/CL2021002512A1/es unknown
- 2021-10-26 CO CONC2021/0014274A patent/CO2021014274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527638A (ja) | 2022-06-02 |
| CN113873998A (zh) | 2021-12-31 |
| SG11202110623PA (en) | 2021-10-28 |
| PE20212366A1 (es) | 2021-12-21 |
| TW202102231A (zh) | 2021-01-16 |
| WO2020205530A1 (en) | 2020-10-08 |
| KR20210143906A (ko) | 2021-11-29 |
| CO2021014274A2 (es) | 2022-01-17 |
| EP3946365A4 (en) | 2023-04-19 |
| US20220184107A1 (en) | 2022-06-16 |
| MX2021011876A (es) | 2022-01-04 |
| EP3946365A1 (en) | 2022-02-09 |
| EA202192663A1 (ru) | 2022-03-01 |
| CA3134828A1 (en) | 2020-10-08 |
| AU2020252005A1 (en) | 2021-11-04 |
| CL2021002512A1 (es) | 2023-01-06 |
| IL286713A (en) | 2021-10-31 |
| BR112021019593A2 (pt) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ford et al. | Plasmenylethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation. | |
| EP3964200A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| MX2022003402A (es) | Grupos principales de compuestos lipídicos y composiciones para la administración intracelular de agentes terapéuticos. | |
| CO2021014831A2 (es) | Lípidos de amina ionizables y nanopartículas lipídicas | |
| MX2022003269A (es) | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. | |
| RU2012144392A (ru) | Композиции липидных везикул и способы применения | |
| NZ595856A (en) | Pharmaceutical composition | |
| AR107285A2 (es) | Vacuna | |
| AR119705A1 (es) | Formulaciones liposomales y sus métodos de uso y preparación | |
| PE20080141A1 (es) | Sistemas estables de nanocapsulas para la administracion de moleculas activas | |
| FI940993A0 (fi) | Salisyylihapon kosmeettinen jakelujärjestelmä ja menetelmä tämän valmistamiseksi | |
| ATE401057T1 (de) | Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen | |
| RU2006137325A (ru) | Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав | |
| JP2014504259A5 (es) | ||
| AR108036A1 (es) | Formulaciones liposomales y métodos de uso de las mismas en agricultura | |
| AR109981A1 (es) | Formulación liposomal | |
| AR082644A1 (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares | |
| Walters et al. | RETRACTED: Visualization of lipid metabolism in the zebrafish intestine reveals a relationship between NPC1L1-mediated cholesterol uptake and dietary fatty acid | |
| AR086105A1 (es) | Agentes de reduccion de la deriva de pulverizacion que comprenden tensioactivos de bajo equilibrio hidrofilo-lipofilo | |
| CO2021011652A2 (es) | Ésteres de ácido graso como agentes anti-malassezia | |
| Vermehren et al. | Lung surfactant as a drug delivery system | |
| MX2007007859A (es) | Composiciones comestibles las cuales comprenden un lipido primario, un co-lipido y un ingrediente fisiologicamente activo lipofilico y agua, y su preparacion. | |
| RU2019134554A (ru) | Липосомальные композиции и содержащие их твердые пероральные лекарственные формы | |
| WO2023250197A3 (en) | Lipid structures and compositions comprising same | |
| DK1077717T3 (da) | Anvendelse af lipopeptider eller lipoproteiner til sårbehandling |